Compounded GLP-3: What 503A Pharmacies Can Legally Do

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

"Compounded" GLP-1 refers to a patient-specific medication prepared by a licensed compounding pharmacy under a valid prescription. Compounded products are legally and factually different from FDA-approved brand medications and are not FDA-approved generics. This article covers what compounding pharmacies can and cannot do, what changed after the FDA shortage resolutions for semaglutide and tirzepatide, how compounded products compare to brand products, and where common compounded variations such as added B12 or lower-dose protocols may fit when clinically appropriate.

What a 503A compounding pharmacy can legally do

503A pharmacies are state-licensed compounders that prepare medications for individually identified patients based on a valid prescription. A 503A pharmacy generally may not compound, regularly or in inordinate amounts, a medication that is essentially a copy of a commercially available FDA-approved drug. If a commercially available product could be used by the same route and in the same, similar, or easily substitutable strength, a prescriber must determine and document why the compounded version produces a significant difference for that individual patient. State pharmacy boards and the FDA both play oversight roles, and legality depends on the specific drug, formulation, pharmacy, prescription, patient need, and current FDA policy.

What the 2024–2025 shortage resolutions changed

During the FDA-declared shortages of semaglutide and tirzepatide, some compounders relied on shortage-related pathways to prepare versions of these medications. That changed when FDA determined that the tirzepatide injection shortage was resolved and later determined that the semaglutide injection shortage was resolved. FDA’s shortage-based enforcement discretion periods for 503A compounding have ended for both tirzepatide and semaglutide, and semaglutide and tirzepatide do not currently appear on FDA’s drug shortage list or the 503B bulks list. As a result, broad copy-style compounding of these drugs is much more restricted than it was during the shortage period. Patient-specific compounding may still be evaluated under 503A rules when the prescription is not an essentially copied commercially available product and the prescriber documents a clinically significant difference for the identified patient.

How compounded products compare to brand products

Compounded products are not the same as FDA-approved brand products, and they are not generics. FDA-approved medications undergo premarket review for safety, effectiveness, quality, labeling, manufacturing, and dosing instructions. Compounded medications do not undergo that same FDA approval process before dispensing. They may differ in strength, concentration, route, vehicle, excipients, combinations, storage requirements, beyond-use date, and pharmacy-specific quality controls. Quality can vary by pharmacy, so patients should confirm state licensure, prescription requirements, sterility practices when applicable, labeling, lot or batch information, beyond-use date, storage instructions, and whether any testing or quality documentation is available.

Common compounded variations

Some compounded GLP-1 formulations include additional ingredients such as cyanocobalamin, a form of vitamin B12, or use strengths, concentrations, vehicles, or dose schedules that differ from commercially available products. These variations should be patient-specific and clinically justified by the prescribing provider. B12 should not be treated as a universal requirement or a proven way to improve GLP-1 outcomes, and FDA has noted that a compounded product combining semaglutide with another API such as vitamin B12 may still be considered essentially a copy of a commercially available product in certain circumstances. "Microdose" formulations are also customized approaches rather than standardized FDA-approved dosing schedules. PlexusDx offers a Microdose GLP-1 Protocol as one of its Weight Management Protocols.

Safety considerations

Verify that the compounding pharmacy is licensed and that a qualified prescribing provider conducts a real clinical evaluation, reviews contraindications, explains the exact medication and formulation, and provides clear dosing and follow-up instructions. Be wary of vendors that ship without prescriptions, sell "research chemical" products, accept only cryptocurrency or wire transfer, or use vague pharmacy information. Compounded products should include patient-specific labeling, lot or batch information, beyond-use dates, storage instructions, and appropriate handling instructions. Sterile injectable preparations should be compounded under applicable sterile-compounding standards such as USP <797>; nonsterile preparations are governed by USP <795>; USP <800> applies to hazardous-drug handling when relevant.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R that may shape baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1?.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs conversations about GLP-1 and incretin-pathway protocols. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide pathways, including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds. Compounded medications are not FDA-approved and are not generics. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not diagnose disease, determine medication eligibility, or predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What is compounded GLP-1?

Compounded GLP-1 generally refers to a patient-specific formulation prepared by a licensed compounding pharmacy under a valid prescriber order. It is legally and factually different from an FDA-approved brand product and is not a generic. The formulation may involve a different strength, concentration, vehicle, ingredient combination, or route-specific preparation, but it must comply with applicable federal and state compounding rules.

Is compounded GLP-1 the same as the brand?

No. Compounded products are not FDA-approved brand products and are not FDA-approved generics. They do not undergo the same FDA premarket review for safety, effectiveness, quality, manufacturing, labeling, and dosing instructions. They may differ in strength, concentration, vehicle, excipients, combinations, storage instructions, beyond-use date, and pharmacy-specific quality controls. PlexusDx Weight Management Protocols use licensed pharmacy pathways and publish per-protocol pricing.

Why do some compounded formulations include B12?

Cyanocobalamin, a form of vitamin B12, is sometimes included in compounded formulations when a provider determines it is clinically appropriate for an individual patient. It should not be treated as universally necessary or as proof that a compounded product is superior. FDA has noted that semaglutide combined with another API such as vitamin B12 may still be considered essentially a copy of a commercially available product in certain circumstances, so patient-specific clinical documentation matters.

Does genetic testing predict response to compounded GLP-1?

No. The Precision Peptide Genetic Test does not predict response to compounded semaglutide, tirzepatide, or any specific compound, dose, route, or formulation. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that may shape baseline GLP-1, appetite-regulation, and energy-balance biology — upstream context that can support a more informed conversation with a qualified healthcare provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education